KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress

Key Terms

subcutaneous medical

Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

monoclonal antibody medical

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

patient-reported outcomes medical

Reports provided directly by patients about their symptoms, daily functioning, and quality of life—collected through surveys, apps, or interviews—reflecting how a treatment affects real people rather than lab measures. Investors care because these firsthand accounts help regulators, doctors and payers judge a product’s real-world value and can influence approval, pricing, adoption and long-term sales; think of them as customer reviews that show whether a medical product truly improves everyday life.

on-label regulatory

On-label describes using a medicine or medical device exactly as approved by regulators, matching the condition, dose, patient group and instructions on the official product label. For investors, on-label use matters because it typically means predictable sales, clearer insurance reimbursement and lower legal or regulatory risk—like using a tool the way its instruction manual recommends versus improvising a new purpose.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company presented its latest research at the Oncology Nursing Society (ONS) Congress, May 13-17. The poster at ONS was titled, “Reducing Ergonomic Strain During Subcutaneous Monoclonal Antibody Administration.”

The ONS abstract evaluated nursing workflow, nurse experience, and patient-reported outcomes after implementing KORU Medical's FreedomEDGE® infusion system for subcutaneous drug administration across four community infusion centers in the United States. The findings demonstrated:

• Efficiency- 100% of doses successfully administered with infusion times aligned with clinical guidelines
• Reduced Strain- Nurses experienced significantly less strain after implementing pump assisted or tubing-needle set assisted drug administration
• High Satisfaction- Both nurses (4.85/5) and patients (4.92/5) reported high satisfaction levels
• Workflow advantages- Nurses reported ability to multitask during 80% of pump infusions

“The learnings from this multi-site study provides encouraging real-world examples of our ability to meet the needs of healthcare providers and patients and improve their experience with subcutaneous drug administration,” said Brent Rutland, KORU Medical’s Vice President, Global Medical and Clinical Affairs. “Presenting our latest research at these esteemed congresses provides a valuable opportunity to share our findings with leading experts in the field of oncology nursing.”

KORU Medical’s FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow rate, and delivered drug volume from 5mL-50mL+, the Freedom System is market proven with:

• 15+ years of patient self-administration in the home
• 59,000+ patients and over 3M infusions annually¹
• 97% adherence rate and 9 on-label subcutaneous drugs²
• Approval in 30+ countries

The ONS Congress, hosted by the Oncology Nursing Society (ONS), is one of the largest professional gatherings dedicated to oncology nursing. It brings together nurses, researchers, educators, and healthcare professionals from around the world to share the latest evidence-based practices, research findings, and innovations in cancer care. The conference features educational sessions, keynote presentations, networking opportunities, and exhibits focused on improving patient outcomes, advancing nursing knowledge, and addressing emerging challenges in oncology.

About KORU Medical Systems

KORU Medical develops, manufactures, and commercializes innovative and patient-centric subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60^® and FreedomEDGE^® Syringe Infusion Drivers, Precision Flow Rate Tubing^™ and High-Flo Subcutaneous Safety Needle Sets^™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

References

1. KORU Medical Estimates and Third-Party Data on File
2. Rutland B, Bosshard J, Southworth C. Enhancing Drug Adherence and Patient Outcomes: The Role of SCIG Pump Selection in Subcutaneous Immunoglobulin Therapy for Primary Immunodeficiency Disease. Poster presented at: National Home Infusion Association Annual Conference; March 23-27, 2024; Austin TX.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260518943304/en/

Investor Contact:
Louisa Smith
investor@korumedical.com

Source: KORU Medical Systems, Inc.